Adverse events that occurred in 10% or more of patients (any CTC grade) and/or were of CTC grade 3 or higher
| Adverse event . | Any CTC grade . | CTC grade ≥3 . |
|---|---|---|
| All patients of the safety population, N (%) | 40 | 40 |
| Anemia, n (%) | 3 (7.1) | 3 (7.1) |
| Arthralgia, n (%) | 6 (14.3) | 0 |
| Back pain, n (%) | 5 (11.9) | 0 |
| Constipation, n (%) | 9 (21.4) | 1 (2.4) |
| COVID-19, n (%) | 26 (61.9) | 9 (21.4) |
| Diarrhea, n (%) | 15 (35.7) | 1 (2.4) |
| Dizziness, n (%) | 9 (21.4) | 0 |
| Fatigue, n (%) | 12 (28.6) | 0 |
| Headache, n (%) | 7 (16.7) | 0 |
| Hematoma, n (%) | 8 (19.0) | 1 (2.4) |
| Hyperuricemia, n (%) | 4 (10.0) | 1 (2.4) |
| Infusion-related reaction, n (%) | 15 (35.7) | 1 (2.4) |
| Leukopenia,∗ n (%) | 5 (11.9) | 4 (9.5) |
| Nausea, n (%) | 12 (28.6) | 0 |
| Neutropenia,† n (%) | 12 (28.6) | 10 (23.8) |
| Pneumonia,‡ n (%) | 7 (16.7) | 5 (11.9) |
| Pyrexia, n (%) | 5 (11.9) | 0 |
| Rash, n (%) | 7 (16.7) | 0 |
| Sepsis, n (%) | 1 (2.4) | 1 (2.4) |
| Thrombocytopenia,§ n (%) | 14 (33.3) | 7 (16.7) |
| Tumor lysis syndrome, n (%) | 3 (7.1) | 3 (7.1) |
| Vomiting, n (%) | 5 (11.9) | 0 |
| Adverse event . | Any CTC grade . | CTC grade ≥3 . |
|---|---|---|
| All patients of the safety population, N (%) | 40 | 40 |
| Anemia, n (%) | 3 (7.1) | 3 (7.1) |
| Arthralgia, n (%) | 6 (14.3) | 0 |
| Back pain, n (%) | 5 (11.9) | 0 |
| Constipation, n (%) | 9 (21.4) | 1 (2.4) |
| COVID-19, n (%) | 26 (61.9) | 9 (21.4) |
| Diarrhea, n (%) | 15 (35.7) | 1 (2.4) |
| Dizziness, n (%) | 9 (21.4) | 0 |
| Fatigue, n (%) | 12 (28.6) | 0 |
| Headache, n (%) | 7 (16.7) | 0 |
| Hematoma, n (%) | 8 (19.0) | 1 (2.4) |
| Hyperuricemia, n (%) | 4 (10.0) | 1 (2.4) |
| Infusion-related reaction, n (%) | 15 (35.7) | 1 (2.4) |
| Leukopenia,∗ n (%) | 5 (11.9) | 4 (9.5) |
| Nausea, n (%) | 12 (28.6) | 0 |
| Neutropenia,† n (%) | 12 (28.6) | 10 (23.8) |
| Pneumonia,‡ n (%) | 7 (16.7) | 5 (11.9) |
| Pyrexia, n (%) | 5 (11.9) | 0 |
| Rash, n (%) | 7 (16.7) | 0 |
| Sepsis, n (%) | 1 (2.4) | 1 (2.4) |
| Thrombocytopenia,§ n (%) | 14 (33.3) | 7 (16.7) |
| Tumor lysis syndrome, n (%) | 3 (7.1) | 3 (7.1) |
| Vomiting, n (%) | 5 (11.9) | 0 |
Including preferred terms “leukopenia” and “white blood cell count decreased.”
Including preferred terms “neutropenia” and “neutrophil count decreased.”
Including preferred terms “pneumonia,” “pneumonia pseudomonal,” and “pneumonia fungal.”
Including preferred terms “thrombocytopenia” and “platelet count decreased.”